Supplementary Figure S4 from Camizestrant in Combination with Three Globally Approved CDK4/6 Inhibitors in Women with ER+, HER2− Advanced Breast Cancer: Results from SERENA-1

Key Points

• Results indicate improved overall response rates in women receiving camizestrant with CDK4/6 inhibitors, highlighting combinatorial efficacy.
• Median progression-free survival was significantly extended for the cohort treated with camizestrant, indicating prolonged benefit.
• Subgroup analysis across pooled data from various trials provides comprehensive insight into treatment effectiveness.
• These findings support the potential for integrating camizestrant in treatment regimens for advanced breast cancer.